Bill & Melinda Gates Foundation
P.O. Box 23350
Seattle
Washington
98102
United States
Tel: 206-709-3100
Website: http://www.gatesfoundation.org/
Email: info@gatesfoundation.org
220 articles about Bill & Melinda Gates Foundation
-
Researchers have published a study of a woman being called the "Esperanza patient," one of what researchers call "elite controllers," who seem to eradicate HIV naturally.
-
Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials
11/10/2021
Inventprise, a biotechnology company specializing in novel, affordable and highly impactful vaccines, announced that the Bill & Melinda Gates Foundation, a global non-profit organization, has made a program-related investment in the company’s continued development of IVT-25, an investigational pneumococcal conjugate vaccine designed to prevent pneumococcal bacterial infections.
-
Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries
10/25/2021
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic
-
Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.
-
PharmaJet, WHO and BMGF Conduct Somalia Polio Vaccination Campaign
10/21/2021
PharmaJet®, the maker of innovative, needle-free injection technology, announced that its Tropis® intradermal needle-free injection system is being used in a campaign in Somalia delivering inactivated polio vaccine to more than 110,000 children.
-
Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources
10/20/2021
The Bill & Melinda Gates Foundation announced a commitment of up to $120 million to accelerate access to the investigational antiviral drug molnupiravir for lower-income countries as part of its COVID-19 response effort.
-
Tadataka “Tachi” Yamada, a former GlaxoSmithKline and Takeda Pharmaceutical executive, early gene therapy backer, and philanthropist, passed away on Wednesday of natural causes at the age of 76.
-
A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.
-
Praedicare Inc. Receives Grant to Evaluate Potential New Drug Regimens for Tuberculosis
6/17/2021
Praedicare Inc. today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicare’s in vitro hollow fiber model of Tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.
-
Zoetis A.L.P.H.A. Initiative Improves Livestock Health and Farmers’ Livelihoods in Sub-Saharan Africa with 1.7 billion Doses of Vaccines and Medicines administered in Four Years
6/10/2021
Livestock health and farmers’ livelihoods have been dramatically improved in Sub-Saharan Africa, following the administration of 1.7 billion doses of vaccines and medicines and over 650,000 diagnostic tests through Zoetis’ African Livestock Productivity and Health Advancement initiative, now in its fourth year.
-
California Startup, BiologyWorks, Born During the COVID-19 Pandemic Improves Molecular Testing Today and Tomorrow
5/26/2021
BiologyWorks™, a medical test developer with a mission to deliver fast and accurate molecular testing, launches its innovative and affordable BiologyWorks k™ test.
-
The Foundation will offer funding for development of the therapy.
-
Evestra Receives Grant to Develop Female Health Product for Developing Countries
2/2/2021
Evestra, Inc. announced that the Bill & Melinda Gates Foundation has given a grant to Evestra to advance preclinical and clinical development of a novel long-acting injectable contraceptive product for women in underserved regions such as Sub-Saharan Africa.
-
Bill and Melinda Gates Release 2021 Annual Letter: "The Year Global Health Went Local"
1/27/2021
Bill and Melinda Gates share their 2021 Annual Letter, "The Year Global Health Went Local." In this year's letter, Bill and Melinda reflect on the worldwide impact of COVID-19 and the global collaboration and scientific innovation fueling one of the largest public health efforts in history.
-
It’s been a busy day so far for biopharma news and updates. Read on for more.
-
Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world
12/10/2020
Gates Foundation pledges additional $250 million to accelerate development and equitable distribution of COVID-19 tests, treatments, and vaccines to end the pandemic
-
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
11/16/2020
Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option to Help Address the HIV Epidemic with Focus on Women in Sub-Saharan Africa
-
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
11/11/2020
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments using its CRISPR/Cas9 genome editing technology. This pilot development program is part of the Gates Foundation’s broade
-
Just - Evotec Biologics Receives Grant to Enable an Antibody Product for The Prevention of Covid-19
10/19/2020
Evotec SE announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.
-
Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries
10/8/2020
Eli Lilly and Company and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, to benefit low- and middle-income countries.